The pharmaceutical industry has made significant advances in collaboration over the past two years, and I...
OPINION
Experts Point of View
Despite a couple of notable 'firsts' for European public biotech financing, biotech's COVID-19 bubble may be...
Medicines for rare and paediatric diseases have been successfully enabled through the EU’s incentives...
The past two years could be called the years of messenger RNA (mRNA) technology, with two major biotech...
The COVID-19 pandemic has demonstrated how vulnerable human beings and societies are to a new infectious...
New entrants and variants will be main drivers of the COVID-19 vaccine market as supply gradually begins
to...
Share
